Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Mild to Heavy Alcohol Consumption
Interventions: Oxycodone; Other
Lead sponsor: University of Washington; Other
Eligibility: 35 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Temporomandibular Disorders
Interventions: Chiropractic w/Activator & Self Care, Dental Care & Self Care, Sham AMCT, Self-Care Only Group; Device · Other
Lead sponsor: Palmer College of Chiropractic; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Coralville, Iowa • Davenport, Iowa • Iowa City, Iowa

Conditions: Opioid-use Disorder
Interventions: Peer-Facilitated Counseling, Fitbit activity tracker; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Fall River, Massachusetts

Conditions: Diabetic Macular Edema (DME)
Interventions: AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg; Drug
Lead sponsor: AsclepiX Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more

Conditions: Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
Interventions: Avapritinib; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Stanford, California • Chicago, Illinois • Westwood, Kansas + 9 more

Conditions: Food-drug Interaction
Interventions: Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg; Dietary Supplement · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Myeloid, Acute
Interventions: BAY1436032; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Buffalo, New York • New York, New York • The Bronx, New York + 4 more

Conditions: Healthy, Male
Interventions: Zanubrutinib, Rifabutin; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Pharmacokinetics
Interventions: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Lacerations, Pain, Procedural, LET
Interventions: LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 7 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Orange, California • Torrance, California

Conditions: Thermal Burns
Interventions: cP12; Drug
Lead sponsor: Neomatrix Therapeutics, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetic Foot Ulcer (DFU)
Interventions: Xcell Amnio Matrix, Standard of Care (SOC); Biological · Drug
Lead sponsor: New Horizon Medical Solutions; Network
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Fresno, California • San Diego, California • Dallas, Texas

Conditions: Sickle Cell Disease, Malnutrition
Interventions: Maternal Nutrition Education, Standard Care; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Months to 18 Months
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Elbow Fracture
Interventions: Glucocorticoids, Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gonorrhoea
Interventions: AZD0914, Ceftriaxone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: Vericiguat (Verquvo, BAY1021189); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Alzheimer Disease
Interventions: 18F-MK-6240, 11C-PIB; Drug
Lead sponsor: José A. Luchsinger; Other
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Warfarin, Dexpramipexole; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Melanoma
Interventions: Exercise Intervention, Wellness Intervention; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Macular Edema Secondary to Retinal Vein Occlusion
Interventions: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein; Drug · Diagnostic Test
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Fullerton, California • Long Beach, California • Mountain View, California + 48 more

Conditions: Pain, Chronic
Interventions: Online Telerehabilitation Platform Access, Usual care; Other
Lead sponsor: Brooks Rehabilitation; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Endometriosis
Interventions: Ultravision™ Visual Field Clearing System, Ultravision Ionwand™; Device
Lead sponsor: Mercy Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Tobacco Use Cessation
Interventions: Opt Out Treatment Program, Nicotine Replacement Therapy, Opt In Treatment Program; Behavioral · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Intensive Care Unit Acquired Weakness (ICUAW)
Interventions: FES-Cycling, Standard Care; Device · Other
Lead sponsor: Associate Professor Sue Berney PhD, BPT; Other
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Search by objective public record fields.

Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users

Conservative Treatment of Patients With Temporomandibular Disorders

Transforming Recovery Through Exercise and Community

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Licorice Botanical Dietary Supplements - Metabolism and Safety in Women

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

Comparison of Two Application Techniques for LET Gel

A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

Prevention of Malnutrition in Children With Sickle Cell Disease

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Post Discharge Online Telerehabilitation Program

Ultravision™ System to Facilitate Low Impact Laparoscopic Surgery for Endometriosis

Changing the Default for Tobacco Treatment

eStimCycle: Early Rehabilitation in Critical Care